|
WO2021072198A1
|
|
Oral complement factor d inhibitors
|
|
WO2021072156A1
|
|
Oral complement factor d inhibitors
|
|
WO2021026182A1
|
|
Process-scale synthesis of a plasma kallikrein inhibitor
|
|
WO2021021909A1
|
|
Dosing regimens for oral complement factor d inhibitors
|
|
WO2020210368A1
|
|
Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
|
|
TW202031255A
|
|
Crystalline salts of a plasma kallikrein inhibitor
|
|
TW202010742A
|
|
Substituted benzofuran, benzopyrrole,benzothiophene, and structurally related complement inhibitors
|
|
AR112027A1
|
|
ALK 2 KINASE INHIBITORS CONTAINING IMIDAZOLE
|
|
CA3041058A1
|
|
Prodrugs of kallikrein inhibitors
|
|
TW201731515A
|
|
Methods and compositions for treatment of Zika virus infection
|
|
TW201733983A
|
|
Benzopyrazole compounds and analogues thereof
|
|
AU2016262644A1
|
|
Intravenous antiviral treatments
|
|
KR20180058815A
|
|
Human plasma calichein inhibitor
|
|
WO2017035263A1
|
|
Compositions comprising a plasma kallikrein inhibitor
|
|
AU2015305214A1
|
|
Compositions and uses of amidine derivatives
|
|
WO2016029216A2
|
|
Method for producing amidine derivatives
|
|
MA39719B1
|
|
Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikrein
|
|
AU2015226855A1
|
|
Human plasma kallikrein inhibitors
|
|
CA2911424A1
|
|
Anti-influenza imino-ribose pyrrolopyrimidine derivatives
|
|
WO2014078778A2
|
|
Antiviral azasugar-containing nucleosides
|
